Myriad Genetics

MYGNNasdaq United States Health Care Biotechnology: In Vitro & In Vivo Diagnostic Substances

Market cap

$311.818 M

$3.26 +2.52%

Close of 7 Aug 2026

Revenue

$824.5M

#1642 by revenue

Earnings

-$366.0M

Loss-making

Shares outstanding

95,649,645

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: In Vitro & In Vivo Diagnostic Substances — ranked by market cap

All 19 →

#9Achieve Life SciencesACHV$682.7M
#10Alpha TeknovaTKNO$346.3M
#11Myriad GeneticsMYGN$311.8M
#12Insight Molecular DiagnosticsIMDX$156.0M
#13ImmucellICCC$99.5M

Where these numbers come from

Share counts and financials for Myriad Genetics are taken from its own SEC filings via EDGAR — public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 9 Aug 2026. Read the methodology.